8-K: Interpace Biosciences to Restate Prior Financial Statements Due to Royalty Expense Accrual Error

Interpace Biosciences will restate financial statements from 2023 and 2024 due to an error in the accrual of royalty expenses, which overstated liabilities and will positively impact stockholders' equity and net income.

Summary

• Interpace Biosciences has determined it will restate its previously issued financial statements for the year ended December 31, 2023, and the quarterly periods ended March 31, June 30, and September 30 of both 2023 and 2024.
• The restatement is due to the determination that the accrual of certain royalty expenses was not required.
• The company's management concluded that accrued royalties and total liabilities were overstated by approximately $5.3 million at March 31, 2023, increasing to $6.3 million by December 31, 2023.
• The overstatement continued into 2024, reaching approximately $7.1 million by September 30, 2024.
• The company will amend its annual report on Form 10-K for the year ended December 31, 2023, to reflect a $6.0 million reduction in the royalty accrual.
• The company will also amend its quarterly reports on Form 10-Q for the affected periods to reflect the reversal of accrued royalty expenses, which amount to approximately $0.3 million to $0.4 million per quarter.
• The company will not be restating any financial statements prior to 2023, however, the impact on the financial years of 2015-2022 totaled approximately $4.8 million in the aggregate.
• The restated financial statements are not expected to result in any material change to the company's revenues or consolidated statements of cash flows.
• The company intends to strengthen its internal controls over financial reporting.
• Management has discussed these matters with EisnerAmper LLP and the company's Audit Committee.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the need for a financial restatement, indicating past accounting errors. However, the impact on revenue and cash flow is expected to be immaterial, and the company is taking steps to improve internal controls, which mitigates some of the negative sentiment.

Positives

• The reversal of accrued royalties expense is expected to have a positive impact on stockholders' equity and net income.
• The restated financial statements are not expected to result in any material change to the company's revenues or consolidated statements of cash flows.
• The company plans to strengthen its internal controls over financial reporting.

Negatives

• Previously issued financial statements for 2023 and 2024 should no longer be relied upon.
• Management's Evaluation of Disclosure Controls and Procedures and Management's Annual Report on Internal Control over Financial Reporting included in Item 9A of the Annual Report on Form 10-K for the year ended December 31, 2023 should no longer be relied on.
• A material weakness relating to assessment of accrued royalty expenses will be reported.

Risks

• The preparation of the restated financial statements or other subsequent events could require the company to make additional financial statement adjustments.
• There are inherent limitations in internal control over financial reporting.

Future Outlook

The company disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise, except as required by law.

Management Comments

• The company's management has discussed the matters disclosed under Item 4.02(a) of this Current Report on Form 8-K with EisnerAmper as well as the company's Audit Committee.

Industry Context

Restatements due to accounting errors are not uncommon, particularly in complex areas like royalty accruals. Investors often scrutinize these events closely as they can indicate weaknesses in a company's internal controls and financial reporting processes. Companies in the biotechnology and pharmaceutical sectors, which often have complex licensing agreements and royalty structures, may be more prone to such issues.

Comparison to Industry Standards

• It's difficult to directly compare Interpace Biosciences' situation to specific industry benchmarks without knowing the precise nature of their royalty agreements.
• However, similar companies like Exact Sciences or Genomic Health (now part of Exact Sciences) have faced scrutiny regarding revenue recognition and accounting practices in the past.
• The materiality of the restatement, in terms of its impact on key financial metrics like revenue and cash flow, will be a key factor in assessing the severity of the issue.
• A restatement that only affects balance sheet items (like accrued liabilities) is generally viewed as less serious than one that impacts the income statement or cash flow statement.

Stakeholder Impact

• Shareholders should be aware that previously issued financial statements should no longer be relied upon.
• The company's reputation may be temporarily affected by the restatement.
• Employees involved in financial reporting may face increased scrutiny and training.

Next Steps

• The company will amend its Annual Report on Form 10-K for the year ended December 31, 2023.
• The company will amend its Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, June 30, and September 30 of both 2023 and 2024.
• The company will strengthen its internal controls over financial reporting.

Key Dates